About The Meeting:

Dr. Metallo will discuss how his laboratory applies stable isotope tracing and mass spectrometry-based metabolomics to understand how dysregulation of endogenous metabolic pathways drives diseases such as cancer, diabetes, and neuropathy. Specific areas of focus:

• Application of metabolic flux analysis (MFA) to quantitatively study cellular and organismal physiology

• Modulation of tumor growth and neuropathy phenotypes by diet and pharmacological interventions

• Role of enzyme promiscuity in metabolism and disease

Bio:

Christian Metallo joined UC San Diego in 2011 and is currently an associate professor in the Department of Bioengineering. He received his BS in chemical engineering from the University of Pennsylvania in 2000 before joining Merck Research Laboratories to conduct bioprocess engineering research. He received his Ph.D. from the University of Wisconsin-Madison Department of Chemical and Biological Engineering in 2008 and was an American Cancer Society Postdoctoral Fellow in Chemical Engineering at the Massachusetts Institute of Technology.

The Metallo lab aims to elucidate how metabolism contributes to disease, with a focus on redox, amino acid, and lipid biochemistry and their impact on cancer, diabetes, and neurodegeneration. They apply a combination of cell engineering, analytical chemistry/mass spectrometry-based metabolomics, and systems biology/metabolic flux analysis approaches to accomplish this goal.

Christian Metallo joined UC San Diego in 2011 and is currently an associate professor in the Department of Bioengineering. He received his BS in chemical engineering from the University of Pennsylvania in 2000 before joining Merck Research Laboratories to conduct bioprocess engineering research. He received his Ph.D. from the University of Wisconsin-Madison Department of Chemical and Biological Engineering in 2008 and was an American Cancer Society Postdoctoral Fellow in Chemical Engineering at the Massachusetts Institute of Technology.

Dr. Metallo was the recipient of the Biomedical Engineering Society Rita Schaffer Young Investigator Award in 2012 and a Searle Scholar Award in 2013. He received a 2015 NSF CAREER Award and a Camille and Henry Dreyfus Teacher-Scholar Award in 2017. The lab is funded by a combination of government, foundation, and industrial research support.

Our June 2019 meeting is generously sponsored by:

Silver Sponsors

Q2 Solutions

BioIVT

For more information on sponsoring SCDMDG, please refer to our sponsorship guidelines.

Prior presentations:

Note: slides are displayed in a new window, left-click to advance, right-click to go back.

Speaker	PDF	Topic	Date
Rob Knight, Ph.D.		Human Microbiome and Metabolome Dynamics	May 30, 2017
Kim L. R. Brouwer, Pharm.D., Ph.D.		Altered Disposition of Drugs and Bile Acids in Patients with Non-Alcoholic Steatohepatitis (NASH)	December 7, 2016
Les Benet, Ph.D.		The Use of BDDCS in Drug Development: The Observations, The Predictions, Understanding the Scientific Basis and The Extensions	April 19, 2016
Nicholas J. Schork, Ph.D.		Design and Implementation Issues in Clinical Trials Advancing Personalized Medicine	September 15, 2015
Robert P. Hanzlik, Ph.D.		Reactive Metabolites, Cellular Targets and Beyond	April 28, 2015
J. Ernest Simpson, Ph.D.		The Chemistry Of Wine	October 28, 2014
Lawrence J. Marnett, Ph.D., F.C.P		Next Generation NSAIDs That Selectively Inhibit Endocannabinoid Metabolism by COX-2	May 6, 2014
Lawrence J. Lesko, Ph.D., F.C.P.		Drug Interaction Studies: Differences and Similarities in How to Meet the Regulatory Expectations in FDA Guidance and EMA Guidelines	May 14, 2013
Thomas Tozer, Ph.D.		Pharmacokinetics of Protein Drugs	October 23, 2012
Shujuan Chen		Application of Animal Models for Human Glucuronidation	October 23, 2012
Caroline Decker		The Use of Modified Bacterial CYPs for Metabolite Generation	October 23, 2012
Mary Dwyer, Ph.D.		Cancer Therapeutics: A Novel Approach	October 23, 2012
Justin Hoffman PharmD MS		Population Pharmacokinetics (PK) of LopinavirDuring Pregnancy and Postpartum	October 23, 2012
David A. Yee		Observations on the Urine Metabolic Ratio of Oxymorphone to Oxycodone in Pain Patients	October 23, 2012
Nabil Hanna, Ph.D.		The Discovery and Development of Rituxan	April 10, 2012
Dr. Richard Kim		Drug Transporters: In Vitro and Knockout Model Systems, Pharmacogenomics, and Clinical Relevance	April 19, 2011
Dr. Jerry Galluppi		Biotherapeutic Drug Research and Development: A Growing Role for the DMPK Scientist	October 5, 2010
Dr. Dennis Smith		Does drug metabolism hold its future in its own hands?	April 27, 2010
Dr. Paul F. Hollenberg		Mechanism-Based Inactivation of Human Cytochromes P450	October 6, 2009
Dr. Jack H. Dean Dr. Thomas Baillie		Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective	May 19, 2009
Eric Johnson, Ph.D.		Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography	September 30, 2008
Dr. Kenneth E. Thummel, Ph.D.		Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics	May 7, 2008
Dr. Anthony Lu, Ph.D.		Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme?	September 12, 2007
Dr. Scott Obach, Ph.D.		Leveraging ADME Data In Metabolites In Safety Testing (MIST)	April 18, 2007
Dr. Sidney Nelson, Ph.D.		Drug Metabolism and Chemical Structural Alerts	September 27, 2006
Richard B. Kim, MD		Relevance and Utility of Transporters to Drug Discovery and Development	September 21, 2005
Dr. Frederick P. Guengerich, Ph.D.		Human Cytochrome P450 2A6 as a Case History:  Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450	April 27, 2005
Dr. Leslie Benet, Ph.D.		Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS	September 29, 2004
Dr. Christopher A. Lipinski, Ph.D.		ADME/Tox: How Low Can You Go And How Do You Recover?	April 21, 2004